Can Fite Biopharma Ltd (CANF) — Net Asset Quality Index
Can Fite Biopharma Ltd (CANF) has a Net Asset Quality Index of 58.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ILA9.51 Million minus total liabilities of ILA3.92 Million yields net assets of ILA5.59 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read Can Fite Biopharma Ltd (CANF) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Can Fite Biopharma Ltd Net Asset Quality Index Over Time (2003–2025)
This chart shows how Can Fite Biopharma Ltd's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the index stands at 58.8%, representing net assets of ILA5.59 Million against total assets of ILA9.51 Million ILA. For live market cap and overall valuation, see Can Fite Biopharma Ltd stock valuation.
Annual Net Asset Quality Index for Can Fite Biopharma Ltd (2003–2025)
The table below presents the year-by-year Net Asset Quality Index for Can Fite Biopharma Ltd from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Can Fite Biopharma Ltd (CANF) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (ILA) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 58.8% | ILA5.59 Million | ILA9.52 Million | ILA3.92 Million | ▼ -0.8 pp |
| 2024 | 59.6% | ILA5.44 Million | ILA9.12 Million | ILA3.68 Million | ▼ -2.9 pp |
| 2023 | 62.5% | ILA6.24 Million | ILA9.99 Million | ILA3.75 Million | ▲ +14.3 pp |
| 2022 | 48.2% | ILA4.47 Million | ILA9.28 Million | ILA4.81 Million | ▼ -22.8 pp |
| 2021 | 71.0% | ILA14.38 Million | ILA20.25 Million | ILA5.87 Million | ▲ +7.2 pp |
| 2020 | 63.8% | ILA6.07 Million | ILA9.52 Million | ILA3.45 Million | ▲ +33.9 pp |
| 2019 | 29.9% | ILA2.44 Million | ILA8.17 Million | ILA5.73 Million | ▼ -8.0 pp |
| 2018 | 37.9% | ILA3.02 Million | ILA7.95 Million | ILA4.94 Million | ▼ -1.1 pp |
| 2017 | 39.0% | ILA3.05 Million | ILA7.83 Million | ILA4.78 Million | ▲ +0.9 pp |
| 2016 | 38.1% | ILA3.87 Million | ILA10.17 Million | ILA6.29 Million | ▼ -21.2 pp |
| 2015 | 59.3% | ILA10.44 Million | ILA17.60 Million | ILA7.16 Million | ▼ -8.0 pp |
| 2014 | 67.3% | ILA6.86 Million | ILA10.19 Million | ILA3.33 Million | ▲ +0.1 pp |
| 2013 | 67.2% | ILA4.46 Million | ILA6.63 Million | ILA2.18 Million | ▲ +110.5 pp |
| 2012 | -43.3% | ILA-707.99K | ILA1.64 Million | ILA2.34 Million | ▼ -110.4 pp |
| 2011 | 67.1% | ILA3.29 Million | ILA4.90 Million | ILA1.61 Million | ▼ -3.4 pp |
| 2010 | 70.5% | ILA13.07 Million | ILA18.55 Million | ILA5.47 Million | ▲ +3.4 pp |
| 2009 | 67.1% | ILA13.49 Million | ILA20.10 Million | ILA6.62 Million | ▼ -0.6 pp |
| 2008 | 67.7% | ILA14.79 Million | ILA21.86 Million | ILA7.07 Million | ▼ -11.4 pp |
| 2007 | 79.1% | ILA38.70 Million | ILA48.94 Million | ILA10.23 Million | ▼ -12.7 pp |
| 2006 | 91.8% | ILA38.34 Million | ILA41.76 Million | ILA3.42 Million | ▼ -4.8 pp |
| 2005 | 96.6% | ILA35.83 Million | ILA37.09 Million | ILA1.26 Million | ▲ +237.8 pp |
| 2004 | -141.2% | ILA-1.81 Million | ILA1.28 Million | ILA3.09 Million | ▼ -217.5 pp |
| 2003 | 76.3% | ILA2.07 Million | ILA2.71 Million | ILA642.00K | — |